Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Entyvio | vedolizumab | Ulcerative Colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xospata | Gilteritinib | Reimburse with clinical criteria and/or conditions | Complete | |||
| Beovu | brolucizumab | Macular degeneration, age-related | Reimburse with clinical criteria and/or conditions | Complete | ||
| Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Contrave | naltrexone hydrochloride and bupropion hydrochloride | Chronic weight management in adults | Do not reimburse | Complete | ||
| Kisqali | Ribociclib | HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Adcetris | Brentuximab Vedotin | peripheral T-cell lymphoma (PTCL) | Reimburse | Complete | ||
| Cuvposa | glycopyrrolate | chronic severe drooling, neurologic (pediatric) | Do not reimburse | Complete | ||
| Tecentriq & Avastin | Atezolizumab & Bevacizumab | NSQ-NSCLC | Do not reimburse | Complete | ||
| Stelara/Stelara I.V | ustekinumab | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 27, 2024